BNXTF.US BioNxt Solutions Inc.

Healthcare Pharmaceuticals USA Stocks
0.1540 USD
Close of Nov 13, 2026
0.1001 0.5269
Market cap
USD 21.0M
P/E
-
P/B
21.77x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is BNXTF.US undervalued?

Graham number

The Graham number of BioNxt Solutions Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

BioNxt Solutions Inc. fundamental analysis

No fundamental analysis for BioNxt Solutions Inc. yet.

BioNxt Solutions Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About BioNxt Solutions Inc.

BioNxt Solutions Inc. engages in research, development, manufacture, and sale of next generation drug formulations and delivery systems in Austria, Germany, and Switzerland. The company provides BNT23001for the treatment of multiple sclerosis and myasthenia gravis; BNT24002 for the treatment of lupus nephritis; BNT24003 for the treatment of rheumatoid arthritis; BNT24004 for longevity and anti-aging; BNT24005 for solid organic transplantation; and BNT24006, an oncology drug …

Full company profile